close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbCellera Biologics Inc. - Common Shares (NQ:ABCL)

5.675 -0.455 (-7.42%)
Streaming Delayed Price Updated: 3:48 PM EDT, Jun 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about AbCellera Biologics Inc. - Common Shares

< Previous 1 2 3 4 5 Next >
News headline image
AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Present at Upcoming Investor Conferences in May and June 2026
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Reports Full Year 2025 Business Results
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Present at Upcoming Investor Conferences in March and April 2026
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Report Full Year 2025 Financial Results on February 24, 2026
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera and Bruker Reach Global Settlement of Patent Litigation
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Appoints Dr. Stephen Quake to its Board of Directors
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Reports Q3 2025 Business Results
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Participate at Upcoming Investor Conferences in November and December 2025
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Participate at Upcoming Investor Conferences in September
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera’s Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Reports Q1 2025 Business Results
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Participate at Upcoming Investor Conferences in May and June
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Reports Full Year 2024 Business Results
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Participate at Upcoming Investor Conferences in March
From AbCellera Biologics Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today